QuidelOrtho Reports Significant Q1 Loss and Revenue Decline, Announces $100M Acquisition
Summary
QuidelOrtho reported a significant Q1 2026 net loss and revenue decline, alongside a shift to negative operating cash flow, while also announcing a $100 million acquisition of LEX Diagnostics.
Key Events
-
Significant Revenue Decline
Total revenues decreased by 11% to $619.8 million in Q1 2026, down from $692.8 million in Q1 2025, primarily due to lower respiratory product sales and the termination of a joint business arrangement.
-
Shift to Operating Loss
The company reported an operating loss of $31.8 million in Q1 2026, a significant reversal from the operating income of $32.6 million in Q1 2025.
-
Widened Net Loss
Net loss increased substantially to $91.8 million (EPS $(1.35)) in Q1 2026, compared to a net loss of $12.7 million (EPS $(0.19)) in the prior year period.
-
Negative Operating Cash Flow
Cash flow from operating activities turned negative, with $33.0 million used in Q1 2026, a sharp contrast to $65.6 million provided in Q1 2025.
Analysis
QuidelOrtho's Q1 2026 results detail a substantial financial downturn, confirming the preliminary announcement from the recent 8-K. The company experienced a significant revenue decrease, a shift from operating income to a considerable operating loss, and a widened net loss. This financial deterioration is compounded by negative operating cash flow. Concurrently, the company disclosed a material acquisition of LEX Diagnostics for $100 million, funded by new debt, which represents a significant capital allocation during a challenging period. Investors should note the immediate financial headwinds alongside the strategic investment in molecular diagnostics.
At the time of this filing, QDEL was trading at $11.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $793.8M. The 52-week trading range was $10.86 to $38.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.